Add BrightSurf on Google Email

Brigham and Women's Hospital


Published data from Moderna COVID-19 vaccine trial show 94.1 percent efficacy

The Moderna COVID-19 vaccine has demonstrated a 94.1 percent efficacy in preventing symptomatic COVID-19 infections and severe illness, according to the results of the ongoing phase 3 clinical trial. The study enrolled over 30,000 participants and found that cases of severe COVID-19 occurred only in those who received the placebo.

SourceBrigham and Women's Hospital·JournalNew England Journal of Medicine·DateDec 30, 2020